Press Releases April 29, 2026 04:17 PM

Athene Holding Ltd. Declares Second Quarter 2026 Preferred Stock Dividends

Athene Holding Ltd. announces preferred stock dividends for Q2 2026 across multiple series.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
ATHN

Athene Holding Ltd. declared quarterly preferred stock dividends for its Series A, B, D, and E preferred shares, with dividend payments scheduled for June 30, 2026. The depositary shares representing these preferred stocks are listed on the NYSE under tickers ATHPrA, ATHPrB, ATHPrD, and ATHPrE. Athene continues its commitment to providing retirement solutions, managing $440 billion in assets.

Athene Holding Ltd. Declares Second Quarter 2026 Preferred Stock Dividends
ATHN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Declared quarterly preferred stock dividends for four series of preferred shares payable June 30, 2026.
  • Preferred shares depositary receipts are listed on the NYSE under respective ticker symbols ATHPrA, ATHPrB, ATHPrD, and ATHPrE.
  • Athene manages $440 billion in assets and operates in multiple countries focusing on retirement and savings products.

WEST DES MOINES, Iowa, April 29, 2026 (GLOBE NEWSWIRE) -- Athene announced that it has declared the following preferred stock dividends on its non-cumulative preferred stock (represented by depositary shares, each representing a 1/1,000th interest in a share of preferred stock), payable on June 30, 2026 to holders of record as of June 15, 2026.

  • Quarterly dividend of $396.875 per share on the company’s 6.35% Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock, Series A (the “Series A Preferred Stock”); holders of depositary shares will receive $0.396875 per depositary share.
  • Quarterly dividend of $351.5625 per share on the company’s 5.625% Fixed-Rate Perpetual Non-Cumulative Preferred Stock, Series B (the “Series B Preferred Stock”); holders of depositary shares will receive $0.3515625 per depositary share.
  • Quarterly dividend of $304.6875 per share on the company’s 4.875% Fixed-Rate Perpetual Non-Cumulative Preferred Stock, Series D (the “Series D Preferred Stock”); holders of depositary shares will receive $0.3046875 per depositary share.
  • Quarterly dividend of $484.375 per share on the company’s 7.750% Fixed-Rate Reset Perpetual Non-Cumulative Preferred Stock, Series E (the “Series E Preferred Stock”); holders of depositary shares will receive $0.484375 per depositary share.

Depositary shares for the Series A Preferred Stock are listed on the New York Stock Exchange (“NYSE”) under the ticker symbol “ATHPrA,” depositary shares for the Series B Preferred Stock are listed on the NYSE under the ticker symbol “ATHPrB,” depositary shares for the Series D Preferred Stock are listed on the NYSE under the ticker symbol “ATHPrD,” and depositary shares for the Series E Preferred Stock are listed on the NYSE under the ticker symbol “ATHPrE.”

About Athene
Athene is the leading retirement solutions company with $440 billion of total assets as of December 31, 2025, and operations in the United States, Bermuda, Canada, and Japan. Athene is focused on providing financial security to individuals by offering an attractive suite of retirement income and savings products and also serves as a solutions provider to corporations. For more information, please visit www.athene.com.

Contact
Jeanne Hess
VP, External Relations
+1 646 768 7319
jeanne.hess@athene.com


Risks

  • Dividend payments are non-cumulative, implying that missed payments do not accumulate, posing income uncertainty for investors in adverse conditions.
  • Market interest rate fluctuations could affect the attractiveness and valuation of fixed-to-floating and fixed-rate preferred stock.
  • Economic downturns impacting retirement savings and corporate clients may affect Athene's asset management and dividend sustainability.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026